Patent application number | Description | Published |
20080269191 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 10-30-2008 |
20080280869 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 11-13-2008 |
20090203752 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 08-13-2009 |
20090253699 | Compounds for Nonsense Suppression, and Methods for Their Use - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 10-08-2009 |
20110086833 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY - The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA. | 04-14-2011 |
20110160164 | COMPOUNDS FOR NONSENSE SUPPRESSION AND METHODS FOR THEIR USE - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 06-30-2011 |
20110172284 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY - Described herein are methods for the identification or validation of compounds capable of causing ribosomal frameshifting and the use of said compounds to produce a stabilized SMNΔEx7 protein and treat Spinal Muscular Atrophy. | 07-14-2011 |
20110213005 | METHODS FOR TREATING VIRAL INFECTIONS - The present invention relates to compounds that modulate ribosomal frameshifting and nucleic acid constructs for use in methods for identifying or validation such compounds. In particular, the present invention relates to the use of nucleic acid constructs to identify or validate compounds capable of modulating the efficiency of programmed ribosomal frameshifting and the use of said compounds to inhibit the replication or infectivity of viruses that employ programmed ribosomal frameshifting. | 09-01-2011 |
20140135305 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY - The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA. | 05-15-2014 |
20140235586 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 08-21-2014 |
20150119380 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY - Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively. | 04-30-2015 |
20150126515 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY - Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. | 05-07-2015 |
20150274674 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES - The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | 10-01-2015 |
Patent application number | Description | Published |
20080275233 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE - The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions. | 11-06-2008 |
20110046136 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH - The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene. | 02-24-2011 |
20110130391 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE - The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions. | 06-02-2011 |
20120087896 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS - Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith. | 04-12-2012 |
Patent application number | Description | Published |
20100317334 | APPLICATION SERVICE INVOCATION - An Internet Protocol Multimedia Subsystem (IMS) includes a Serving-Call Session Control Function (S-CSCF). The S-CSCF includes a Service Capability Interaction Manager (SCIM) configured to invoke one or more application services in response to a message being received by the S-CSCF. | 12-16-2010 |
20110231540 | POLICY ENGINE IN AN INTERNET PROTOCOL MULTIMEDIA SUBSYSTEM - A system includes a policy engine in an Internet Protocol Multimedia Subsystem (IMS). The policy engine may be configured to store a group of policies associated with the IMS, and forward the group of policies to a group of policy components in the IMS. | 09-22-2011 |
20120020350 | APPLICATION SERVICE INVOCATION BASED ON FILTER CRITERIA - An Internet Protocol Multimedia Subsystem (IMS) device includes a memory configured to store a subscriber profile, where the subscriber profile includes at least one criterion relating to an event that occurs after a session request has been forwarded to a terminating party. The IMS device further includes a processor configured to invoke at least one application service for a session based on the at least one criterion in the subscriber profile. | 01-26-2012 |
20120237014 | ROUTING CALLS IN A NETWORK - A method includes receiving a telephone number mapping query associated with a call. The method may also include generating routing information based on the query and forwarding the routing information to a control device. The routing information may indicate that processing associated with routing the call is to bypass a core portion of an Internet multimedia subsystem (IMS) when a calling party associated with the call does not invoke an IMS service, the called party associated with the call does not invoke an IMS service and the called party is not an IMS subscriber. | 09-20-2012 |